Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLK2 | Q9NYY3 | 7/20 | 1.00 |
| ▸ | NEK2 | P51955 | 1/20 | 1.00 |
| ▸ | NEK5 | Q6P3R8 | 1/20 | 1.00 |
| ▸ | NEK1 | Q96PY6 | 1/20 | 1.00 |
| ▸ | KIT | P10721 | 2/20 | 0.64 |
| ▸ | LCK | P06239 | 1/20 | 0.64 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.64 |
| ▸ | FLT3 | P36888 | 1/20 | 0.64 |
| ▸ | PLK1 | P53350 | 1/20 | 0.64 |
| ▸ | RPS6KA1 | Q15418 | 1/20 | 0.64 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.64 |
| ▸ | WNK2 | Q9Y3S1 | 1/20 | 0.64 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.45 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.45 |
| ▸ | MAPK14 | Q16539 | 5/20 | 0.45 |
| ▸ | EGFR | P00533 | 3/20 | 0.45 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.45 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.45 |
| ▸ | SRC | P12931 | 2/20 | 0.45 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31305062 | 1.00 | PLK2 (1.00) | PLK2NEK2NEK5NEK1KIT | |
| SCHEMBL13385843 | 0.90 | PLK2 (1.00) | PLK2NEK2NEK5NEK1KIT | |
| SCHEMBL1995285 | 0.88 | PLK2 (0.79) | PLK2NEK2NEK5NEK1KIT | |
| SCHEMBL13385789 | 0.84 | PLK2 (0.80) | PLK2NEK2NEK5NEK1KIT | |
| SCHEMBL1989414 | 0.84 | PLK2 (1.00) | PLK2NEK2NEK5NEK1KIT | |
| SCHEMBL13385884 | 0.83 | PLK2 (0.85) | PLK2NEK2NEK5NEK1KIT | |
| SCHEMBL13385852 | 0.83 | PLK2 (1.00) | PLK2NEK2NEK5NEK1KIT | |
| SCHEMBL13385769 | 0.83 | PLK2 (0.84) | PLK2NEK2NEK5NEK1KIT | |
| SCHEMBL13385811 | 0.83 | PLK2 (0.87) | PLK2NEK2NEK5NEK1KIT | |
| SCHEMBL13385894 | 0.83 | PLK2 (0.84) | PLK2NEK2NEK5NEK1KIT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8889696-B2 | Substituted pyrido[2,3-d]pyrimidin-7(8H)-ones and therapeutic uses thereof | Temple University—Of the Commonwealth System of Higher Education (US) | 2014-11-18 | — | — | US | claimed |
| US-8889696-B2 | Substituted pyrido[2,3-d]pyrimidin-7(8H)-ones and therapeutic uses thereof | Temple University—Of the Commonwealth System of Higher Education (US) | 2014-11-18 | — | — | US | disclosed |
| US-8889696-B2 | Substituted pyrido[2,3-d]pyrimidin-7(8H)-ones and therapeutic uses thereof | Temple University—Of the Commonwealth System of Higher Education (US) | 2014-11-18 | — | — | US | disclosed |
| US-20120269831-A1 | SUBSTITUTED PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONES AND THERAPEUTIC USES THEREOF | TEMPLE UNIVERSITY- OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2012-10-25 | — | — | US | disclosed |
| US-20120269831-A1 | SUBSTITUTED PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONES AND THERAPEUTIC USES THEREOF | TEMPLE UNIVERSITY- OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2012-10-25 | — | — | US | disclosed |
| EP-2512250-A1 | SUBSTITUTED PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONES AND THERAPEUTIC USES THEREOF | Temple University - Of The Commonwealth System of Higher Education (US) | 2012-10-24 | — | — | EP | disclosed |
| WO-2011075616-A1 | SUBSTITUTED PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONES AND THERAPEUTIC USES THEREOF | TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2011-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120269831-A1 | SUBSTITUTED PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONES AND THERAPEUTIC USES THEREOF | MKI67, CCNA1, FOLR1 | PLK2 224/4885NEK2 336/4885NEK5 964/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.